ArticleAmerican journal of cancer research2017
MiR-421 inhibits the malignant phenotype in glioma by directly targeting MEF2D.
Article in American journal of cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 61 citations in OpenAlex.
- Multi-Omics Integration for Advancing Glioma Precision Medicine.Annals of clinical and translational neurology · 2026Review
- Inhibition of hepatocellular carcinoma progression by artesunate via modulation of the TLR4/MyD88/NF-κB signaling pathway.Journal of gastrointestinal oncology · 2025Article
- A multi-omics approach for biomarker discovery in neuroblastoma: a network-based framework.NPJ systems biology and applications · 2024Article
- TBX15 facilitates malignant progression of glioma by transcriptional activation of TXDNC5.iScience · 2024Article
- Hypoxia-driven M2-polarized macrophages facilitate the epithelial-mesenchymal transition of glioblastoma via extracellular vesicles.Theranostics · 2024Article
- circTP63 promotes prostate cancer progression via miR-421/VAMP associated protein A axis.Journal of Cancer · 2024Article
- CircSEC24A (hsa_circ_0003528) interference suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells via miR-421/MMP3 axis.Bioengineered · 2022Article
- miR-363-3p induces EMT via the Wnt/β-catenin pathway in glioma cells by targeting CELF2.Journal of cellular and molecular medicine · 2021Article
- Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells.Cellular & molecular biology letters · 2021Review
- Circ_0001367 inhibits glioma proliferation, migration and invasion by sponging miR-431 and thus regulating NRXN3.Cell death & disease · 2021Article
- Long noncoding RNA DLGAP1-AS1 promotes the progression of glioma by regulating the miR-1297/EZH2 axis.Aging · 2021Observational
- MiR-421 Aggravates Neurotoxicity and Promotes Cell Death in Parkinson's Disease Models by Directly Targeting MEF2D.Neurochemical research · 2021Article
- Roles of Non-coding RNAs and Angiogenesis in Glioblastoma.Frontiers in cell and developmental biology · 2021Review
- FGF14-AS2 accelerates tumorigenesis in glioma by forming a feedback loop with miR-320a/E2F1 axis.Journal of Cancer · 2021Article
- The COX10-AS1/miR-641/E2F6 Feedback Loop Is Involved in the Progression of Glioma.Frontiers in oncology · 2021Article
- Circ_WWC3 overexpression decelerates the progression of osteosarcoma by regulating miR-421/PDE7B axis.Open life sciences · 2021Article
- Article
- CircCPA4 Promotes the Malignant Phenotypes in Glioma via miR-760/MEF2D Axis.Neurochemical research · 2020Article
- Article
- MicroRNA-561 Affects Proliferation and Cell Cycle Transition Through PTEN/AKT Signaling Pathway by Targeting P-REX2a in NSCLC.Oncology research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA-421 (miRNA-421) dysregulation has been found in various human tumors, however, the biological function and molecular mechanism of miR-421 in glioma remain unclear. In this study, we investigated the potential biological roles of miR-421 in glioma cell lines. First, we demonstrated that compared with that of low grade gliomas (LGG), miR-421 expression is much lower in high grade gliomas (HGG) within the CGGA (Chinese Glioma Genome Atlas) database. MiR-421 expression in 5 normal brain tissues and 20 glioma tissues were in agreement with the result in the CGGA. Second, exogenous expression of miR-421 inhibited glucose metabolism, invasion, angiogenesis and enhanced the radiosensitivity in glioma cell lines. Third, through an online database, myocyte enhancer factor 2D (MEF2D) was identified as a target of miR-421. Interestingly, down-regulation of MEF2D led to an inhibitory effect on glioma glucose metabolism, invasion, angiogenesis and enhancing effect on radiosensitivity, which was similar to the effects of the up-regulation of miR-421. Simultaneously, overexpression of MEF2D partially restored the effect of miR-421 on the glioma cell lines. Finally, in a xenograft model, overexpression of miR-421 suppressed tumorigenicity. These data collectively suggested miR-421 may suppress tumor-associated activity in gliomas by targeting MEF2D.
Indexed as
Identifiers
28469958PMC5411793W2965530782What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.